# TILT Biotherapeutics

Source: https://onco.cc/companies/tilt-biotherapeutics/  
OnCo record `tilt-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TILT Biotherapeutics is a Finnish biotech founded by Akseli Hemminki whose oncolytic adenovirus TILT-123 produces TNF-alpha and IL-2 in the tumour to help checkpoint inhibitors and TIL therapy work.

## Summary

TILT Biotherapeutics develops armed oncolytic adenoviruses that replicate in cancer cells and express immune cytokines. TILT-123 (igrelimogene litadenorepvec) carries genes for tumour necrosis factor alpha and interleukin-2, and has been tested with pembrolizumab in platinum-resistant ovarian cancer, with avelumab in solid tumours and with tumour-infiltrating lymphocyte therapy in melanoma. The company has also received funding for phase 2 development in ovarian cancer.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: TILT Biotherapeutics Ltd
- Tags: drug-maker
- HQ: Helsinki
- Type: biotech
- Website: https://www.tiltbio.com/

## Sources

- Official website: https://www.tiltbio.com/

## Connected records

- drugs: [TILT-123](https://onco.cc/drugs/tilt-123/)

---
JSON: https://onco.cc/api/v1/entities/tilt-biotherapeutics.json